health

A promising experimental treatment to lower lipoprotein A

Lipoprotein is a major risk factor for heart disease. D.B.A

Specialists at Cleveland Clinic announced the results of the first phase of a clinical trial, which showed that a single dose of an experimental treatment succeeded in reducing blood levels of lipoprotein (a), which is one of the main risk factors for heart disease, by more than 94% for about a year.

The results of the study, entitled: “Efficacy and safety of lipodesiran: a long-term study of short interfering lipoprotein (A) that targets RNA,” were presented during a scientific session held recently, within the framework of the activities of the 2023 scientific session of the American Heart Association, The results of the study were also published simultaneously in the Journal of the American Medical Association.

Lipoprotein A (LPA) is produced in the liver and has properties similar to low-density lipoprotein (LDL), known as “bad cholesterol.”

Unlike other cholesterol particles, lipoprotein (a) levels are determined by genes by 80 to 90%, and the structure of lipoprotein (a) particles causes plaque to accumulate in the arteries, which significantly increases the risk of heart attacks and strokes.

Despite the availability of effective therapeutic methods to reduce the risk of heart attacks by reducing harmful cholesterol and other types of lipoproteins, there is not yet any approved drug treatment to reduce lipoprotein (a) levels, which, given that they are determined by the genes that the individual carries. Any change in lifestyle (diet or exercise) will not have any noticeable effect.

Trial participants who were injected with the highest dose of lipodesiran recorded a reduction in lipoprotein (A) levels by up to 96% within two weeks, and subsequently maintained lower levels of more than 94% below baseline for a period of 48 weeks.

The drug is a short interfering RNA (siRNA) treatment, which blocks the production of messenger RNA needed to manufacture one of the most important components of lipoprotein (a).